Vendor Intelligence Report: Zenith Jove Peptide ZJ

Published 12 Jun 2026. 23-page investigative report on who is behind Zenith Jove Peptide ZJ: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 53 Finnrick lab tests, Zenith Jove Peptide ZJ shows 47 pass and 6 fail, an overall pass rate of 89%. The useful read is product-specific: Retatrutide and GHK-Cu are the cleaner lines on present evidence; Tirzepatide carries the cautionary GLP-1 signal, and BPC-157 trails the stronger products. ZJ's rating story is also methodology-sensitive because purity-focused scoring is more forgiving than models that punish fill accuracy.

The highest-severity finding is not a percentage. A February correction event documents a vial submitted as Tirzepatide containing Semaglutide, in a vendor system that ships completely unlabeled vials and relies on cap colors or kit context. For buyers holding multiple products, that makes ordinary storage and kit mixing part of the safety problem.

The identity layer is stronger than the website layer. ZJ publicly uses Guangzhou ZJ Biotechnology Co., Ltd., and a COA image corroborates that name, but no Chinese registry extract was retrieved, leaving ownership unresolved. The site is a young PbootCMS build with a random Gmail, Hong Kong contact layer, and UK WhatsApp-link artifact. Shared hosting and product-code overlap with Kerui suggest a common vendor environment, not proven common ownership.

The sales interface also cuts both ways: named reps receive forum praise, while Telegram numbers tied to Myanmar, Morocco, and the U.S. complicate channel verification. Reddit scam complaints and ZJ's own scam alert sit close in time, but missing Telegram logs leave real-vendor versus impersonator attribution unresolved.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 4 tested products
  • Correction-event analysis covering the Tirzepatide/Semaglutide mix-up and unlabeled-vial practice
  • Corporate and website forensics for the Guangzhou ZJ Biotechnology identity, Xinnet domain record, PbootCMS captures, Gmail, and phone artifacts
  • Kerui comparison across Cloudie hosting, boilerplate language, product codes, and unresolved ownership questions
  • Representative contact map, Telegram-number anomalies, scam-alert timeline, payment-recourse, and China-shipping risk assessment

Risk assessment

  • Product misidentification risk from unlabeled vials — high: ZJ ships unlabeled vials and Finnrick documented a February 26, 2026 case in which a vial submitted as Tirzepatide contained Semaglutide.
  • Tirzepatide quantity-control concern — high: Field materials attribute Tirzepatide failures to fill variability; Finnrick records 22 tests, 18 pass / 4 fail, and an 80.52% rating for Tirzepatide.
  • BPC-157 weak testing signal — medium: BPC-157 stands at 6 tests, 5 pass / 1 fail, with a 61% Finnrick rating, materially weaker than ZJ's Retatrutide and GHK-Cu lines.
  • Brand-confusion and impersonation risk — high: ZJ issued an April 16, 2026 scam alert after Reddit complaints; no on-site anti-counterfeit or signed-COA verification system was identified.
  • Operational-transparency concern — medium: The domain was registered September 2, 2025; the site uses template PbootCMS, random-string Gmail, unverified registry data, and anomalous Telegram country codes.
  • Payment-recourse risk — medium: Orders are handled through reps using USDT/Wise/bank wire, leaving buyers with little practical chargeback protection.
  • Cross-border shipping disruption risk — medium: April 2026 China export disruption affected ZJ and peers; no evidence ZJ was targeted, but seizure/enforcement waves can interrupt delivery.